Newsletters

The European Medicines Agency (EMA) publishes newsletters to provide updates on various topics to patients, healthcare professionals and the pharmaceutical industry.

Human medicines highlights, published monthly, contains key information on human medicines and changes to regulatory processes in the past month. These highlights do not cover all the Agency's activities in the area of human medicines.

EMA provides an RSS feed of the human medicines highlights. To subscribe, use the below link and follow our user guide on how to subscribe to RSS feeds:

• Human Medicines Highlights newsletter

EMA does not collect any personal data from you when you subscribe to this RSS feed.

The newsletter for micro-, small- and medium-sized enterprises (SMEs), published four times a year, provides key updates to SMEs on the European regulatory environment.

For older editions, see the Newsletter archive.

• Report on the 10th anniversary of the SME initiative

What's new in pharmacovigilance, published four times a year, updates qualified persons for pharmacovigilance on guidance, regulations and events.

EMA's ‘CTIS newsflash’ contains key updates on the latest developments, including system improvements, and links to useful reference materials.

In March 2022, the 'CTIS highlights' newsletter became the 'Clinical Trials highlights' newsletter. It will continue to cover CTIS but will also include topics such as the business change programme ACT EU. 

To subscribe, write to ct.newslettersubscriptions@ema.europa.eu.

The Veterinary Medicinal Products Regulation highlights, published every two months in 2021, provides an update on progress towards implementing the new Regulation.

To subscribe, write to vetchange.programme@ema.europa.eu.

The Big Data highlights, published every three months, provides an update on progress in implementing the workplan of the HMA-EMA Big Data Steering Group.

To subscribe, write to bigdata@ema.europa.eu.

The digital application dataset integration (DADI) newsletter, published four times a year, provides pharmaceutical companies and the national competent authorities in the EU updates on the progress of the DADI project.

It also includes an overview of upcoming events and information on available resources.

The objective of the DADI project is to replace PDF electronic application forms (eAF) used for regulatory submissions with online forms, in order to make completing and handling applications more efficient. For more information, see:

• eSubmissions: Digital Application Dataset Integration (DADI)